The Biosimilars Market research report identifies the key market trends and focuses on significant trends and driving factors market growth. In addition, the Biosimilars Market examines the global and major regions’ market potentials and benefits, opportunities and challenges, prevention and risk. Finally, the Biosimilars Market research report strategically examines each submarket regarding the Biosimilars Market growth trends and their contribution.
Download the FREE PDF of the Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=270786
List of Companies Profiled in the Report:
- Novartis AG (Switzerland)
- Pfizer, Inc. (US)
- Dr. Reddy’s Laboratories Ltd (India)
- Amgen, Inc. (US)
- Eli Lilly and Company (US)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Fresenius SE & Co. KGaA (Germany)
- STADA Arzneimittel AG (Germany)
- Boehringer Ingelheim (Germany)
- Gideon Richter PLC (Hungary)
- Celltrion (South Korea)
- Samsung Biologics (South Korea)
- CoherusBioSciences (US)
- Biocon Limited (India)
- Viatris, Inc. (US)
- Amega Biotech (Argentina)
- Apotex, Inc. (Canada)
- Biocad (Russia)
- mAbxience (Spain)
- Probiomed SA De CV (Mexico)
- Fujifilm Kyowa Kirin Biologics Co., Ltd. (Japan)
- Intas Pharmaceuticals Ltd. (India)
- Theramex (UK)
- Reliance Life Sciences (India)
- Kashiv Biosciences (US)
The global biosimilars market is expected to reach USD 44.7 billion in 2026 from USD 15.6 billion in 2021, at a CAGR of 23.5% during the forecast period of 2021 to 2026. Market growth is largely driven by rising coverage. chronic diseases and increasing demand of biosimilars for their cost effectiveness. Regulatory approvals and other regulations that favor the adoption of biosimilars in different countries are also a major driving factor in the biosimilars market. However, complexities in the development and manufacture of biosimilars and resistance from reference biologic manufacturers are expected to hinder the growth of this market during the forecast period.
The biosimilars market is split into Europe, Asia Pacific, North America, Latin America and the Middle East and Africa. The APAC market, on the other hand, is expected to be the fastest growing segment of the region during the forecast period due to the presence of many emerging players, less stringent regulations, and increased cooperation with leading and regional markets. players for the development, manufacture and commercialization of biosimilars.
Get a Purchase Discount on this Report @ https://www.reportsnreports.com/purchase.aspx?name=270786
This report provides a detailed picture of the biosimilars market. It aims to estimate the size and future growth potential of the market in various segments such as product, indication and region. The report also includes an in-depth competitive analysis of the major market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying a Report:
The report will help market leaders/new entrants by providing them with the closest estimate of revenue figures for the overall biosimilars market and its sub-segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and develop appropriate strategies in going to market. This report will enable stakeholders to understand the pulse of the market and provide them with information on key market drivers, constraints, trends, challenges and opportunities.
Table of contents
1. Introduction
1.1 Learning Objectives
1.2 Definition of Market
1.2.1 Study Inclusions and Exclusions
Table 1 Biosimilars Market: Inclusions and Exclusions
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered For Study
1.4 Money
1.5 Stakeholders
1.6 Limitations
1.7 Summary Of Changes
2 Research Methodology
2.1 Research Approach
Figure 1 Research Design
2.2 Secondary Data
Figure 2 Secondary Sources
2.3 Basic Data
Figure 3 Primary Data From Primary Sources
Figure 4 Breakdown Of Main Interview: By Company Type, Designation, And Region
2.4 Market Breakdown And Data Triangulation
Figure 5 Data Triangulation Method
2.5 Market Estimation Method
2.5.1 Bottom-Up Approach
2.5.2 Top-Down Approach
Figure 6 Top-Down Approach
Figure 7 Biosimilars Market: Final Market Size (Usd Billion)
2.6 Growth Rate Assumptions/Growth Forecast
2.7 Insights From Primaries
Figure 8 Market Validation From Leading Experts
2.8 Research Assumptions
2.9 Limitations
2.10 Risk Assessment
3 Executive Summary
Figure 9 Biosimilars Market, By Product, 2021 Vs. 2026 (Usd Million)
Figure 10 Biosimilars Market, According to Indication, 2021 Vs. 2026 (Usd Million)
Figure 11 Biosimilars Market, By Region, 2021 Vs. 2026 (Usd Million)
4 Premium Insights
4.1 Biosimilars Market Overview
Figure 12 Rising Incidence of Chronic Illnesses To Drive Market Growth
4.2 North America: Biosimilars Market, By Product And Country (2020)
Figure 13 Insulin Holds the Largest Share of the North American Biosimilars Market In 2020
4.3 Geographical Snapshot Of Biosimilars Market
Figure 14 Asia Pacific To Register Highest Growth During Forecast Period
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
Figure 15 Biosimilars Market: Drivers, Prevention, Opportunities, and Challenges
5.2.1 Drivers
5.2.1.1 Increasing Demand for Biosimilar Drugs Due to Its Cost Effectiveness
5.2.1.2 Rising Geriatric Population And The Rising Incidence Of Chronic Diseases
Figure 16 Geriatric Population, By Region, 2020 Vs. 2030 vs. 2050 (Million)
Figure 17 Incidence Of Diabetes, By Region, 2019 Vs. 2030 vs. 2045 (Million)
5.2.1.3 Shortened Regulatory Approval Process And Concept Of Exchange
Figure 18 Comparison Of Reference Products, Biosimilars, And Convertible Products
5.2.2 Restraint
5.2.2.1 Labor Complications
5.2.2.2 Resistance From Biologics Manufacturers
5.2.3 Opportunities
5.2.3.1 Emerging Markets
5.2.3.2 Patent Expiry Of Blockbuster Biologics And Research Regarding New Indications
Table 2 List of Major Biologics Under Threat of Patent Expiration
5.2.4 Challenges
5.2.4.1 Excessive Competition
5.2.5 Trends
5.2.5.1 Collaborations For Biosimilar Research And Clinical Trials
Table 3 Key Collaborations in the Biosimilars Market (2017–2020)
5.3 Covid-19 Impact Analysis
5.4 Technology Analysis
Table 4 Comparison of Original Biologics With Biosimilars
Table 5 Generic Drugs vs. Biosimilars
5.5 Value Chain Analysis
Figure 19 Value Chain Analysis For Biosimilars
5.6 Ecosystem Market Map
Figure 20 Ecosystem Market Map For Biosimilars
5.7 Supply Chain Analysis
5.8 Analysis of Porter’s Five Forces
Table 6 Porter’s Five Forces: Impact Analysis On the Biosimilars Market
5.8.1 Threats From New Entrants
5.8.2 Threats From Substitutes
5.8.3 Bargaining Power Of Suppliers
5.8.4 Bargaining Power Of Consumers
5.8.5 Intensity of Competition
5.9 Regulatory Landscape
Table 7 Regulatory Landscape For Biosimilars Market
6 Biosimilars Market, By Product
etc..